ZKB/CALL/ELI LILLY & CO/1100/0.01/27.01.25 | Market Closed - Swiss Exchange 08:50:00 24/06/2024 pm IST | ||
| 0.31 CHF | +3.33% |
|
| 1 month | +63.16% | ||
| 3 months | +40.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 0.31 | +3.33% |
| 21/24/21 | 0.3 | -3.23% |
| 18/24/18 | 0.31 | +6.90% |
| 17/24/17 | 0.29 | +3.57% |
Delayed Quote Swiss Exchange
Last update June 24, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | ZKB |
| LLYIEZ | |
| ISIN | CH1305143476 |
| Date issued | 08/03/2024 |
| Strike | 1,100 $ |
| Maturity | 27/01/2025 (217 Days) |
| Parity | 100 : 1 |
| Emission price | 0.28 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.31 CHF |
|---|---|
| Lowest since issue | 0.1 CHF |
| Spread | 0.01 CHF |
| Spread % | 3.13% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
890.1
USD
Average target price
860.5
USD
Spread / Average Target
-3.32%
- Stock Market
- Warrants
- LLYIEZ Warrant
